Research · Take part
These are clinical trials and research studies that people with HLRCC or FH-deficient kidney cancer may be able to join. The list is checked against ClinicalTrials.gov, and the searches below always show the newest studies.
Reviewed by the HLRCC Foundation, Oct 2026. Trial status checked: Nov 1, 2026.
Listing a study is not a recommendation. Ask your care team whether a study fits you. Trial information changes often. Talk to your doctor before joining a trial. HLRCC Foundation does not run or endorse these studies.
A clinical trial is a research study with volunteers. Some test a new treatment; others follow people over time or collect samples to learn more about a condition.
Learn more: Learn about studies (ClinicalTrials.gov) (opens in a new tab) · How clinical trials work (NCI) (opens in a new tab)
The National Cancer Institute runs a long-running study of HLRCC at the NIH Clinical Center in Bethesda, Maryland (NCT00050752, NIH protocol 03-C-0066). People who have or may have HLRCC, and blood relatives of someone with HLRCC or an FH gene change, may be able to join. It is recruiting.
General contact (from the NIH protocol page): NCI Clinical Trials Referral Office, (888) 624-1937, ncimo_referrals@mail.nih.gov.
Learn about the NIH HLRCC studyNIH protocol page (opens in a new tab)ClinicalTrials.gov record NCT00050752 (opens in a new tab)
15 studies: 8 recruiting, 3 not yet recruiting and 4 active but no longer enrolling new people, grouped by topic. Each card links to the full record on ClinicalTrials.gov, where the study team’s contacts are listed.
RecruitingPhase 2
NCT04981509 · Lead sponsor: National Cancer Institute (NCI)
What it tests: Bevacizumab; Erlotinib; Atezolizumab; plus imaging/biopsy procedures
Who can join
Cohort 1 is for people with HLRCC whose kidney cancer is advanced (has grown or spread) and can be measured on scans. A second group is for people with papillary kidney cancer that is not linked to HLRCC.
Where: United States: sites taking new people are in Atlanta, GA; Bethesda, MD (NCI Center for Cancer Research); Columbus, OH; and Houston, TX (13 US sites in total).
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT04981509 (opens in a new tab)Contacts and locations for NCT04981509 (opens in a new tab)
RecruitingPhase 1
NCT06479811 · Lead sponsor: National Cancer Institute (NCI)
What it tests: [212Pb]VMT-alpha-NET; [203Pb]VMT-alpha-NET; 68Ga-DOTATATE
Who can join
Adults with kidney cancer that has spread or cannot be removed may join if their tumor shows a certain marker (somatostatin receptor) on a scan. People with FH-deficient kidney cancer must have had at least one earlier treatment.
Where: Bethesda, MD.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT06479811 (opens in a new tab)Contacts and locations for NCT06479811 (opens in a new tab)
RecruitingPhase 1
NCT05176483 · Lead sponsor: Exelixis
What it tests: Zanzalintinib; Nivolumab; Ipilimumab; Nivolumab + Relatlimab; Prednisone; Docetaxel; DDI Probe Cocktail
Who can join
One group (Expansion Cohort 6) is for adults with advanced non-clear cell kidney cancer, and FH-deficient kidney cancer is one of the allowed types. People in that group must not have had prior systemic treatment for advanced disease.
Where: 122 sites in 13 countries, including 46 in the United States.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT05176483 (opens in a new tab)Contacts and locations for NCT05176483 (opens in a new tab)
RecruitingPhase 2
NCT05768464 · Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
What it tests: Toripalimab; Axitinib
Who can join
Adults with high-risk non-clear cell kidney cancer that was removed by surgery can join, and FH-deficient kidney cancer is one of the listed types.
Where: Nanjing and Nanning, China.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT05768464 (opens in a new tab)Contacts and locations for NCT05768464 (opens in a new tab)
Not yet recruitingPhase N/A
NCT07776483 · Lead sponsor: West China Hospital
What it involves: Patient-Specific Tumor-Informed ctDNA Monitoring
Who can join
Adults with advanced non-clear cell kidney cancer who will get immunotherapy can join, and FH-deficient kidney cancer is one of the listed types.
Where: No locations listed yet.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT07776483 (opens in a new tab)Contacts and locations for NCT07776483 (opens in a new tab)
Not yet recruitingPhase 2
NCT07816770 · Lead sponsor: Fudan University
What it tests: Toripalimab; Axitinib; Deferred Cytoreductive Nephrectomy
Who can join
Adults with advanced non-clear cell kidney cancer whose tumor biopsy shows a certain immune feature (TLS-positive) may join, and FH-deficient kidney cancer is one of the listed types.
Where: No locations listed yet.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT07816770 (opens in a new tab)Contacts and locations for NCT07816770 (opens in a new tab)
Active, not recruitingPhase 2
NCT03635892 · Lead sponsor: Memorial Sloan Kettering Cancer Center
What it tests: cabozantinib; nivolumab
Who can join
This study was for adults with advanced non-clear cell kidney cancer, and FH-deficient kidney cancer is one of the listed conditions. It is no longer enrolling new people.
Where: New Jersey and New York, United States (Memorial Sloan Kettering sites only).
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT03635892 (opens in a new tab)Contacts and locations for NCT03635892 (opens in a new tab)
Active, not recruitingPhase 1/2
NCT05808608 · Lead sponsor: Hao Zeng
What it tests: AK104; Axitinib
Who can join
This study is for adults (18 to 75) with advanced non-clear cell kidney cancer, and FH-deficient kidney cancer is one of the listed types. It is no longer enrolling new people.
Where: Chengdu, Sichuan, China.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT05808608 (opens in a new tab)Contacts and locations for NCT05808608 (opens in a new tab)
Active, not recruitingPhase 2
NCT06638931 · Lead sponsor: Instituto do Cancer do Estado de São Paulo
What it tests: Nivolumab
Who can join
This study was for adults with certain rare advanced cancers, including kidney cancer with FH deficiency. It is no longer enrolling new people.
Where: Recife, São Paulo, Brasília and Rio de Janeiro, Brazil.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT06638931 (opens in a new tab)Contacts and locations for NCT06638931 (opens in a new tab)
Not yet recruitingPhase 1
NCT07716735 · Lead sponsor: Jonsson Comprehensive Cancer Center
What it tests: Mercaptopurine; plus imaging, biopsy and questionnaire procedures
Who can join
Adults (18+) with a disease-causing FH gene change can join if they have HLRCC signs such as skin leiomyomas, uterine fibroids or kidney cancer. People need certain blood test results and a gene test (TPMT/NUDT15) result before joining.
Where: Los Angeles, CA.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT07716735 (opens in a new tab)Contacts and locations for NCT07716735 (opens in a new tab)
Active, not recruitingPhase N/A
NCT04250766 · Lead sponsor: Institut Bergonié
What it involves: Echo-guided uterine biopsy
Who can join
Women aged 35 or older with a suspicious uterine fibroid that needs surgery could join, and having a family cancer syndrome such as hereditary leiomyomatosis was one way a fibroid could count as suspicious. It is no longer enrolling new people.
Where: Bordeaux, France.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT04250766 (opens in a new tab)Contacts and locations for NCT04250766 (opens in a new tab)
RecruitingNot a drug trial (phase N/A)
NCT00050752 · Lead sponsor: National Cancer Institute (NCI)
What it involves: No study treatment (observational study)
Who can join
People who have or may have HLRCC can join, such as people with skin leiomyomas plus kidney cancer or uterine fibroids, or with a kidney tumor type seen in HLRCC. Blood relatives of someone with HLRCC or an FH gene change may also be able to join.
Where: Bethesda, MD.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT00050752 (opens in a new tab)Contacts and locations for NCT00050752 (opens in a new tab)
RecruitingNot a drug trial (phase N/A)
NCT00001238 · Lead sponsor: National Cancer Institute (NCI)
What it involves: No study treatment (observational study)
Who can join
People and their family members with a known or suspected inherited kidney or urologic cancer can join, including families with skin or uterine leiomyomas. The study description names HLRCC as one of the inherited conditions it covers.
Where: Bethesda, MD.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT00001238 (opens in a new tab)Contacts and locations for NCT00001238 (opens in a new tab)
RecruitingPhase N/A
NCT06907095 · Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
What it involves: biological samples
Who can join
Adults at high risk of cancer can join, including people aged 50 or older who carry a harmful FH gene change. The study tests body fluid samples for early cancer detection.
Where: Villejuif, France.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT06907095 (opens in a new tab)Contacts and locations for NCT06907095 (opens in a new tab)
RecruitingPhase N/A
NCT04623502 · Lead sponsor: University of Texas Southwestern Medical Center
What it involves: 13C-Glucose; 13C-Acetate; 13C-Lactate; 13C-Glutamine; 13C-Fructose
Who can join
Adults with a kidney or urinary tract tumor who need surgery or a biopsy can join. HLRCC and FH deficiency are listed among the conditions studied.
Where: Dallas, TX.
Last checked Nov 1, 2026
View on ClinicalTrials.gov NCT04623502 (opens in a new tab)Contacts and locations for NCT04623502 (opens in a new tab)
These ready-made searches open ClinicalTrials.gov and always show the latest studies, including new ones that are not on this page yet.
Based on NCI guidance: What to expect (NCI) (opens in a new tab) · Who pays (NCI) (opens in a new tab)
These earlier studies were open to some people with kidney cancer; HLRCC is not named in their registry records.
Read more: what the NEJM bevacizumab and erlotinib trial means for HLRCC kidney cancer
We share trial news when it happens. Follow our News.
Find an HLRCC specialistTalk to a genetic counselor (opens in a new tab)Contact us
Yes. As of Nov 1, 2026, this page lists 15 studies that include people with HLRCC or FH-deficient kidney cancer: 8 are recruiting, 3 have not started recruiting yet, and 4 are active but no longer enrolling new people. 9 are kidney cancer studies, 2 are about skin and uterine leiomyomas, and 4 are natural history, registry or tissue studies.
It is a long-running National Cancer Institute study at the NIH Clinical Center in Bethesda, Maryland, for people who have or may have HLRCC and their relatives. It studies the condition over time; it is not a drug trial.
Use the ready-made ClinicalTrials.gov searches on this page, then use the location filter on ClinicalTrials.gov. Each study record lists its sites and how to contact the study team.
It depends on the study. Some study teams take calls from patients directly, and others ask for a referral or medical records from your doctor. The study team can tell you.
Ask the study team what the study pays for and what your insurance is expected to cover, including travel. The National Cancer Institute explains who pays for what.
Study details come from ClinicalTrials.gov, last checked Nov 1, 2026. See our disclaimer.
KidneyCAN offers a free Clinical Trial Navigator that can help you find kidney cancer trials. You can also read about it on our Research page or start a search on KidneyCAN’s site.